Rapport Therapeutics, Inc. (NASDAQ:RAPP) is among the best fast money stocks to buy now. Analysts at JMP Securities have reaffirmed their ‘Market Outperform’ rating on Rapport Therapeutics, Inc. (NASDAQ:RAPP) with a price target of $77, implying a potential surge of about 174%. This announcement follows the publication of “stellar results” from the Phase 2a trial for RAP-219 in refractory focal epilepsy. Keeping in view the year-to-date returns posted by Rapport Therapeutics, Inc. (NASDAQ:RAPP), the compa ...